PI3K (Phosphoinositide 3-kinase) is a key signaling enzyme that generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3), a critical second messenger that regulates cell survival, growth, proliferation, and metabolism[^1]. In neurons, PI3K signaling is essential for development, synaptic plasticity, and neuroprotection against various stresses[^2].
There are multiple PI3K classes, with Class I PI3Ks being most relevant to signaling:
- Class IA: p110α (PIK3CA), p110β (PIK3CB), p110δ (PIK3CD)
- Class IB: p110γ (PIK3CG)
Each has distinct cellular functions and expression patterns[^3].
Class I PI3Ks have a characteristic structure:
The regulatory subunit contains:
- Two SH2 domains for receptor binding
- SH3 domain for protein interactions
- Inter-SH2 (iSH2) domain for p110 binding
The catalytic subunit contains:
- Kinase domain
- C2 domain for membrane association
- Ras-binding domain (RBD)
- Helical domain
PI3K is recruited to the membrane via:
- SH2 domain binding to phosphotyrosines
- Direct binding to activated receptors
- Membrane PIP2 substrate availability[^4]
PI3K is activated by:
- Receptor tyrosine kinase activation
- G protein-coupled receptors
- Small GTPases (Ras)
- Integrin signaling
PI3K activates multiple downstream effectors:
- Akt/PKB: Cell survival, metabolism
- PDK1: Activates Akt
- mTOR: Growth, protein synthesis
- GSK-3: Multiple cellular functions
In neurons, PI3K regulates:
- Neurotrophin signaling (Trk receptors)
- Synaptic plasticity (LTP, LTD)
- Neuronal survival
- Dendritic spine morphology[^5]
PI3K/Akt signaling is implicated in AD:
- Neurotrophin signaling deficits
- Tau phosphorylation dysregulation
- Amyloid-beta affects PI3K pathway
- Therapeutic targeting potential
In PD:
- PI3K protects dopaminergic neurons
- LRRK2 affects PI3K signaling
- Neurotrophin (GDNF) signaling requires PI3K
- PINK1/Parkin pathway connections
PI3K is frequently mutated/activated:
- PIK3CA mutations in many cancers
- Oncogenic signaling drives proliferation
- Therapeutic target (PI3K inhibitors)[^6]
Therapeutic strategies include:
- PI3K inhibitors: Cancer therapy (idelalisib, alpelisib)
- PI3K activators: Neuroprotective approaches
- Akt activators: Downstream neuroprotection
- mTOR inhibitors: Modulate downstream signaling
- Combined approaches: PI3K + other therapies[^7]
- Cantley, PI3K signaling (2002)
- Th� et al., PI3K in neurodegeneration (2019)
- Zhang et al., PI3K/Akt in neuronal survival (2017)
- Liu & Liu, PI3K in Alzheimer's (2020)
- Cantrell, DA, Phosphoinositide 3-kinase signal transduction pathways (2001)
- Brunet et al., PI3K/Akt signaling in neurodegeneration (2005)
- Zheng et al., PI3K in Alzheimer's disease pathogenesis (2017)
- Herrup et al., PI3K/Akt/mTOR in neurodegeneration (2013)
- Li et al., Targeting PI3K in Parkinson's disease (2019)
- Kumar et al., Role of PI3K in synaptic plasticity (2020)